Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostatecancer using real-time electromagnetic tracking 30370364 2018 11 14 2452-1094 3 4 2018 Oct-Dec Advances in radiation oncology Adv Radiat Oncol Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostatecancer using real-time electromagnetic tracking. 630-638 10.1016/j.adro.2018.06.004 The aim (...) of this study is to quantify and describe the feasibility, clinical outcomes, and patient-reported outcomes of reduced planning target volume (PTV) margins for prostatecancer treatment using real-time, continuous, intrafraction monitoring with implanted radiation frequency transponder beacons. For this prospective, nonrandomized trial, the Calypso localization system was used for intrafraction target localization in 31 patients with a PTV margin reduced to 2 mm in all directions. A total of 1333 fractions
Contemporary Radiation Treatment of ProstateCancer in Africa: A Ghanaian Experience 30085846 2018 12 07 2378-9506 4 2018 Jul Journal of global oncology J Glob Oncol Contemporary Radiation Treatment of ProstateCancer in Africa: A Ghanaian Experience. 1-13 10.1200/JGO.17.00234 Purpose Data on prostatecancer (PCa) treatment in Africa remains under-reported. We present a review of the management of PCa at the cancer center of the largest tertiary referral facility in Ghana, with emphasis (...) 25220842 Brachytherapy. 2012 Jan-Feb;11(1):6-19 22265434 ProstateCancer. 2013;2013:560857 23476788 Lancet. 2002 Jul 13;360(9327):103-6 12126818 J Urol. 2004 Apr;171(4):1393-401 15017184 Lancet Oncol. 2014 Apr;15(4):464-73 24581940 Afr J Med Med Sci. 2009 Jun;38 Suppl 2:5-13 20229733 Brachytherapy. 2007 Oct-Dec;6(4):267-71 17959423 Glob J Health Sci. 2014 Oct 27;7(1):296-314 25560361 Health Policy Plan. 1998 Jun;13(2):181-8 10180407 J Urol. 2014 Sep;192(3):730-5 24747091 Ann Intern Med. 2017 Oct 3;167
Systems pharmacology using mass spectrometry identifies critical response nodes in prostatecancer 29977602 2018 12 21 2056-7189 4 2018 NPJ systems biology and applications NPJ Syst Biol Appl Systems pharmacology using mass spectrometry identifies critical response nodes in prostatecancer. 26 10.1038/s41540-018-0064-1 In the United States alone one in five newly diagnosed cancers in men are prostatecarcinomas (PCa). Androgen receptor (AR) status and the PI3K-AKT-mTOR signal transduction (...) Rev Urol. 2008 Spring;10(2):111-9 18660852 Cancer Res. 1995 Jan 15;55(2):342-7 7529134 Mol Cell Endocrinol. 2012 Mar 5;350(1):107-17 22155408 Nucleic Acids Res. 2016 Jan 4;44(D1):D481-7 26656494 Cancer Res. 2012 Dec 1;72(23):6142-52 22971343 Cell. 2012 Mar 16;148(6):1089-98 22424221 Nat Genet. 1995 Apr;9(4):401-6 7795646 Cancer Res. 2003 Jul 1;63(13):3799-804 12839976 Proteomics. 2015 Sep;15(18):3193-208 26097198 ProstateCancerProstatic Dis. 2014 Dec;17(4):310-4 25156059 Genes Chromosomes Cancer
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk ProstateCancer After Radical Prostatectomy: SWOG S9921 29624463 2018 06 15 1527-7755 36 15 2018 May 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk ProstateCancer After (...) Radical Prostatectomy: SWOG S9921. 1498-1504 10.1200/JCO.2017.76.4126 Purpose Patients with high-risk prostatecancer after radical prostatectomy are at risk for death. Adjuvant androgen-deprivation therapy (ADT) may reduce this risk. We hypothesized that the addition of mitoxantrone and prednisone (MP) to adjuvant ADT could reduce mortality compared with adjuvant ADT alone. Methods Eligible patients had cT1-3N0 prostatecancer with one or more high-risk factors after radical prostatectomy (Gleason
Prostatecancer Autosynthesis - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing
Efferocytosis and prostatecancer skeletal metastasis: implications for intervention 30035182 2018 11 14 2331-4737 5 5-6 2018 May Oncoscience Oncoscience Efferocytosis and prostatecancer skeletal metastasis: implications for intervention. 174-176 10.18632/oncoscience.440 Roca Hernan H Department of Periodontics and Oral Medicine, University of Michigan, School of Dentistry, Ann Arbor, MI 48109-1078, USA. McCauley Laurie K LK Department of Periodontics and Oral Medicine, University of Michigan (...) , School of Dentistry, Ann Arbor, MI 48109-1078, USA. eng P01 CA093900 CA NCI NIH HHS United States R01 DK053904 DK NIDDK NIH HHS United States Editorial 2018 06 29 United States Oncoscience 101636666 2331-4737 efferocytosis inflammation macrophage prostatecancer skeletal metastasis CONFLICTS OF INTEREST The authors declare no conflicts of interest. 2018 05 02 2018 05 18 2018 7 24 6 0 2018 7 24 6 0 2018 7 24 6 1 epublish 30035182 10.18632/oncoscience.440 440 PMC6049312 Cancer Cell. 2016 Apr 11;29(4
Enzalutamide in Men with Nonmetastatic, Castration-Resistant ProstateCancer. BACKGROUND: Men with nonmetastatic, castration-resistant prostatecancer and a rapidly rising prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that enzalutamide, which prolongs overall survival among patients with metastatic, castration-resistant prostatecancer, would delay metastasis in men with nonmetastatic, castration-resistant prostatecancer and a rapidly rising PSA level (...) . METHODS: In this double-blind, phase 3 trial, we randomly assigned, in a 2:1 ratio, men with nonmetastatic, castration-resistant prostatecancer and a PSA doubling time of 10 months or less who were continuing androgen-deprivation therapy to receive enzalutamide (at a dose of 160 mg) or placebo once daily. The primary end point was metastasis-free survival (defined as the time from randomization to radiographic progression or as the time to death without radiographic progression). RESULTS: A total
Salvage reirradiation for local failure of prostatecancer after curative radiation therapy: Association of rectal toxicity with dose distribution and normal-tissue complication probability models 30370369 2018 11 14 2452-1094 3 4 2018 Oct-Dec Advances in radiation oncology Adv Radiat Oncol Salvage reirradiation for local failure of prostatecancer after curative radiation therapy: Association of rectal toxicity with dose distribution and normal-tissue complication probability models. 673-681 (...) 10.1016/j.adro.2018.06.001 This study aimed to assess the impact of radiation dose on rectal toxicity after salvage external beam radiation therapy (EBRT) with or without a brachytherapy boost for exclusive local failures after the primary EBRT for prostatecancer. Fourteen patients with no severe residual late toxicity after primary EBRT ± brachytherapy were reirradiated after a median time interval of 6.1 years. The median normalized total dose in 2 Gy fractions (NTD 2Gy , α/β ratio = 1.5 Gy
Risk factors for late bowel and bladder toxicities in NRG Oncology prostatecancer trials of high-risk patients: A meta-analysis of physician-rated toxicities 30202809 2018 11 14 2452-1094 3 3 2018 Jul-Sep Advances in radiation oncology Adv Radiat Oncol Risk factors for late bowel and bladder toxicities in NRG Oncology prostatecancer trials of high-risk patients: A meta-analysis of physician-rated toxicities. 405-411 10.1016/j.adro.2018.04.010 A meta-analysis of sociodemographic variables (...) and their association with late (>180 days from start of radiation therapy[RT]) bowel, bladder, and clustered bowel and bladder toxicities was conducted in patients with high-risk (clinical stages T2c-T4b or Gleason score 8-10 or prostate-specific antigen level >20) prostatecancer. Three NRG trials (RTOG 9202, RTOG 9413, and RTOG 9406) that accrued from 1992 to 2000 were used. Late toxicities were measured with the Radiation Therapy Oncology Group Late Radiation Morbidity Scale. After controlling for study, age
Optimizing Anticancer Therapy in Metastatic Non-Castrate ProstateCancer: American Society of Clinical Oncology Clinical Practice Guideline 29608397 2018 05 16 1527-7755 36 15 2018 May 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Optimizing Anticancer Therapy in Metastatic Non-Castrate ProstateCancer: American Society of Clinical Oncology Clinical Practice Guideline. 1521-1539 10.1200/JCO.2018.78.0619 Purpose This clinical (...) practice guideline addresses abiraterone or docetaxel with androgen-deprivation therapy (ADT) for metastaticprostatecancer that has not been treated (or has been minimally treated) with testosterone-lowering agents. Methods Standard therapy for newly diagnosed metastaticprostatecancer has been ADT alone. Three studies have compared ADT alone with ADT and docetaxel, and two studies have compared ADT alone with ADT and abiraterone. Results Three prospective randomized studies (GETUG-AFU 15, STAMPEDE
Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With ProstateCancer. 29561693 2018 06 16 1527-7755 36 18 2018 Jun 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With ProstateCancer. 1823-1830 10.1200 (...) /JCO.2017.75.5371 Purpose To compare the toxicities and cost of proton radiation and stereotactic body radiotherapy (SBRT) with intensity-modulated radiotherapy (IMRT) for prostatecancer among men younger than 65 years of age with private insurance. Methods Using the MarketScan Commercial Claims and Encounters database, we identified men who received radiation for prostatecancer between 2008 and 2015. Patients undergoing proton therapy and SBRT were propensity score-matched to IMRT patients
Primary cryotherapy for localised or locally advanced prostatecancer. BACKGROUND: Traditionally, radical prostatectomy and radiotherapy with or without androgen deprivation therapy have been the main treatment options to attempt to cure men with localised or locally advanced prostatecancer. Cryotherapy is an alternative option for treatment of prostatecancer that involves freezing of the whole prostate (whole gland therapy) or only the cancer (focal therapy), but it is unclear how effective (...) this is in comparison to other treatments. OBJECTIVES: To assess the effects of cryotherapy (whole gland or focal) compared with other interventions for primary treatment of clinically localised (cT1-T2) or locally-advanced (cT3) non-metastaticprostatecancer. SEARCH METHODS: We updated a previously published Cochrane Review by performing a comprehensive search of multiple databases (CENTRAL, MEDLINE, EMBASE), clinical trial registries (ClinicalTrials.gov, World Health Organization International Clinical Trials
Cancer Treatmentâ€“Induced Bone Loss in Women With Breast Cancer and Men With ProstateCancer 29942922 2018 11 14 2472-1972 2 7 2018 Jul 01 Journal of the Endocrine Society J Endocr Soc Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With ProstateCancer. 574-588 10.1210/js.2018-00052 Cancer and cancer therapies can have a negative impact on bone health. Because cancer is a common diagnosis, survivorship concerns for osteoporosis and fragility fractures are an important (...) component of care. This review addresses management of bone health in nonmetastatic cancer survivorship with a focus on breast cancer and prostatecancer. Taxel Pamela P UConn Health Center, Farmington, Connecticut. Faircloth Erika E UConn Health Center, Farmington, Connecticut. Idrees Sana S Saint Vincent's Hospital, Bridgeport, Connecticut. Van Poznak Catherine C University of Michigan Health Center, Ann Arbor, Michigan. eng Journal Article Review 2018 05 21 United States J Endocr Soc 101697997 2472
Survivin polymorphisms and susceptibility to prostatecancer: A genetic association study and an in silico analysis 30034311 2018 11 14 1611-2156 17 2018 EXCLI journal EXCLI J Survivin polymorphisms and susceptibility to prostatecancer: A genetic association study and an in silico analysis. 479-491 10.17179/excli2018-1234 Survivin is a member of the apoptosis inhibitor protein family and its polymorphisms may lead to susceptibility to cancer. The aim of this study was to investigate (...) the possible association of c.-31G>C (rs9904341), c.454G>A (rs2071214), c.*148T>C (rs2239680) and c.*571T>C (rs1042489) polymorphisms of survivin gene with prostatecancer risk and provide some justification using in silico analysis. The 157 men with prostatecancer and 145 healthy controls were included in a case-control study. The studied polymorphisms were genotyped using PCR-RFLP method. An in silico approach was employed to show the possible effects of the polymorphisms on the survivin gene function
Development of sarcosine quantification in urine based on enzyme-coupled colorimetric method for prostatecancer diagnosis 30034310 2018 11 14 1611-2156 17 2018 EXCLI journal EXCLI J Development of sarcosine quantification in urine based on enzyme-coupled colorimetric method for prostatecancer diagnosis. 467-478 10.17179/excli2018-145 An enzyme-coupled colorimetric assay for quantification of urinary sarcosine was developed. The proposed method is a specific reaction based on hydrogen peroxide (...) , respectively. A good linearity was revealed with a coefficient of 0.990. The assay showed no significant interference from ascorbic acid, glucose and bilirubin. In addition, it is extremely specific for sarcosine rather than other amino acids. The determination of sarcosine in human urine displayed high accuracy and good reproducibility. This method is promising to differentiate prostatecancer patients from healthy subjects according to urinary sarcosine level. Altogether, this study provides a rapid
Use of Conservative Management for Low-Risk ProstateCancer in the Veterans Affairs Integrated Health Care System From 2005-2015 29800017 2018 07 10 2018 12 02 1538-3598 319 21 2018 06 05 JAMA JAMA Use of Conservative Management for Low-Risk ProstateCancer in the Veterans Affairs Integrated Health Care System From 2005-2015. 2231-2233 10.1001/jama.2018.5616 Loeb Stacy S Manhattan Veterans Affairs Medical Center, New York, New York. Byrne Nataliya N Department of Urology, New York University (...) Conservative Treatment statistics & numerical data trends Delivery of Health Care, Integrated Humans Logistic Models Male Middle Aged Multivariate Analysis Prostate-Specific Antigen blood ProstaticNeoplasms therapy Risk Factors United States United States Department of Veterans Affairs Veterans Watchful Waiting 2018 5 26 6 0 2018 7 11 6 0 2018 5 26 6 0 ppublish 29800017 2681802 10.1001/jama.2018.5616 PMC6134433 JAMA Oncol. 2017 Oct 1;3(10):1393-1398 27768168 BJU Int. 2017 Jul;120(1):32-39 27611479 J Clin
Screening for ProstateCancer: US Preventive Services Task Force Recommendation Statement. Importance: In the United States, the lifetime risk of being diagnosed with prostatecancer is approximately 13%, and the lifetime risk of dying of prostatecancer is 2.5%. The median age of death from prostatecancer is 80 years. Many men with prostatecancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history (...) of prostatecancer have an increased risk of prostatecancer compared with other men. Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on prostate-specific antigen (PSA)-based screening for prostatecancer. Evidence Review: The USPSTF reviewed the evidence on the benefits and harms of PSA-based screening for prostatecancer and subsequent treatment of screen-detected prostatecancer. The USPSTF also commissioned a review of existing decision analysis models
Prostate-Specific Antigen-Based Screening for ProstateCancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. Importance: Prostatecancer is the second leading cause of cancer death among US men. Objective: To systematically review evidence on prostate-specific antigen (PSA)-based prostatecancer screening, treatments for localized prostatecancer, and prebiopsy risk calculators to inform the US Preventive Services Task Force. Data Sources: Searches of PubMed (...) Extraction and Synthesis: One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality. Main Outcomes and Measures: Prostatecancer and all-cause mortality; false-positive screening results, biopsy complications, overdiagnosis; adverse effects of active treatments. Random-effects meta-analyses were conducted for treatment harms. Results: Sixty-three studies in 104 publications were included (N = 1 904 950). Randomization to PSA screening was